Key Points
- Insider sale: Joanne Quan sold 6,911 shares of Mirum Pharmaceuticals (NASDAQ:MIRM) on Jan. 20 at an average price of $90.27 for about $623,856, reducing her stake by 37.94% to 11,305 shares (≈$1.02M).
- Company performance and outlook: Mirum reported a quarterly revenue beat with revenue up 47.1% and EPS of $0.05 (vs. -$0.10 expected), but analysts still forecast a negative full-year EPS (~-1.43); the consensus rating is a "Moderate Buy" with an average target around $102.58 and several recent price-target increases.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) insider Joanne Quan sold 6,911 shares of the company's stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $90.27, for a total transaction of $623,855.97. Following the completion of the transaction, the insider owned 11,305 shares in the company, valued at approximately $1,020,502.35. This represents a 37.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Mirum Pharmaceuticals Price Performance
Shares of MIRM opened at $93.27 on Thursday. The company has a market capitalization of $4.79 billion, a P/E ratio of -108.45 and a beta of 0.48. Mirum Pharmaceuticals, Inc. has a twelve month low of $36.88 and a twelve month high of $93.99. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. The firm has a 50 day moving average of $76.34 and a 200 day moving average of $70.16.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company had revenue of $133.01 million for the quarter, compared to analysts' expectations of $130.11 million. During the same period last year, the firm posted ($0.30) earnings per share. Mirum Pharmaceuticals's revenue was up 47.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on the company. Robert W. Baird lifted their target price on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an "outperform" rating in a research report on Monday, December 8th. Morgan Stanley lifted their price target on shares of Mirum Pharmaceuticals from $81.00 to $95.00 and gave the company an "overweight" rating in a report on Tuesday, December 9th. HC Wainwright reissued a "buy" rating and issued a $102.00 price objective (up from $81.00) on shares of Mirum Pharmaceuticals in a research note on Tuesday, January 13th. Citigroup restated an "outperform" rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. Finally, Stifel Nicolaus increased their price target on Mirum Pharmaceuticals from $92.00 to $98.00 and gave the stock a "buy" rating in a research note on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $102.58.
Check Out Our Latest Stock Report on Mirum Pharmaceuticals
Institutional Trading of Mirum Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of MIRM. MCF Advisors LLC boosted its holdings in shares of Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company's stock valued at $31,000 after purchasing an additional 185 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Mirum Pharmaceuticals in the third quarter worth about $33,000. Comerica Bank boosted its stake in Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company's stock valued at $40,000 after buying an additional 278 shares during the last quarter. Quarry LP purchased a new position in Mirum Pharmaceuticals during the 3rd quarter valued at approximately $41,000. Finally, CWM LLC increased its stake in Mirum Pharmaceuticals by 30.8% in the 3rd quarter. CWM LLC now owns 683 shares of the company's stock worth $50,000 after acquiring an additional 161 shares during the last quarter.
Mirum Pharmaceuticals Company Profile
(
Get Free Report)
Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.
Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
